index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

155

 

 

MOTS CLES

Anti-HCV Direct Acting Antivirals DAA Treatment Sacroiliitis Pharmacoepidemiology Angiotensin receptor blockers Biologic drug Ankylosing spondylitis Drug reaction BTK protein Endocrine toxicity Ankylosing Pharmacovigilance Systematic review Addiction Antimicrobial Stewardship Stability Alitretinoin Epidemiology Autoimmunity Biological therapy Bacterial Antimicrobials Atopic dermatitis Antibiotic misuse Antibiotics Adalimumab Biomarkers Anticancer drugs Access to care Placebo Anti-TNF Psoriasis Adverse side effects Anti-Bacterial Agents Biologics Axial spondyloarthritis Psoriatic arthritis Management Prostate cancer ASDAS Auto-Diagnostic Glucocorticoids Anxiété Méta-Analyse Etanercept Infliximab Amyloidosis Bacterial rhinosinusitis ArtThese Auto-immune hepatitis Cancer Biologic therapy Vigibase® Arthritis Primary adrenal insufficiency Network meta-analysis Arrhythmia Abus d'antibiotiques Biomédicaments Spondylitis Ethics Aging Albinism Pharmaco-Épidémiologie Graft-versus-host disease Biologic Apre-milast Adolescent Immunotherapy Ustekinumab Quality of life Meta-Analysis Antimicrobiens Cardio-oncology Drug survival Biosimilar Pharmaceuticals Alcohol Atrial fibrillation Burden Biological Therapy Cardiomyopathy Immune-related adverse events Anxiety Autoimmune diseases Azathioprine Sipuleucel-T Apremilast Immune checkpoint inhibitors Dermatology Accelerometer Antimicrobial resistance COVID-19 Pregnancy Spondyloarthritis Acute Myeloid Leukaemia AML Intensive care Beta-lactam antibiotics Antibiotic resistance Angiotensin-converting enzyme inhibitors Cardiotoxicity

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS